Jacob Discovery Fund Adds Cabaletta Bio After 26.5% Monthly Surge
Jacob Discovery Fund established a new position in Cabaletta Bio during Q4 2025, highlighting its CAR-T immunotherapy platform targeting autoimmune diseases. Cabaletta shares closed at $2.96, delivering a 26.50% one-month gain and 37.67% twelve-month return, with a $284.945 million market capitalization.
1. Investment by Jacob Discovery Fund
Jacob Discovery Fund added a new position in Cabaletta Bio during the fourth quarter of 2025, reflecting confidence in the company’s CAR-T platform for autoimmune diseases.
2. Strong Stock Performance
Cabaletta Bio shares closed at $2.96 on February 17, 2026, marking a 26.50% gain over the past month and a 37.67% advance year-over-year, with a market capitalization of $284.945 million.
3. CAR-T Pipeline and Upcoming Data
Cabaletta is developing an autologous CAR-T therapy aimed at transient B-cell depletion to reset patients’ immune systems in autoimmune conditions, with safety, durability and regimen tolerability data expected over the next 12 months.